Magnesium in Liver Cirrhosis

Clalit Health Services

Status and phase: Unknown; Phase 4

Conditions: LIVER CIRRHOSIS

Treatments: Dietary Supplement: magnesium; Dietary Supplement: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01894867

MMC13247-12CTIL

Details and patient eligibility

About

Several studies have shown in patients magnesium deficiency with liver cirrhosis.

Patients with liver cirrhosis showed considerably reduced muscle strength and muscle magnesium.

We suggest addition of magnesium to patients with established cirrhosis in order to reduce the neuromuscular and neuropsychiatric manifestations of chronic liver disease.

Full description

Magnesium is the fourth most abundant cation in the body and plays an important physiological role in many of its functions.

There are no readily available and easy methods to assess magnesium status but it is estimated that magnesium deficiency is a common problem.

Magnesium deficiency can cause a wide variety of features including hypocalcaemia, hypokalaemia and cardiac and neurological manifestations. Chronic low magnesium state has been associated with a number of chronic diseases including diabetes, hypertension, coronary heart disease, and osteoporosis.

There are not enough studies on magnesium status in chronic cirrhotics who may be in depletion. However , several studies have shown in patients magnesium deficiency with liver cirrhosis. Patients with liver cirrhosis showed considerably reduced muscle strength and muscle Mg . Magnesium may have a role in the neuromuscular and neuropsychiatric manifestations of chronic liver disease (hepatic encephalopathy and muscle cramps).

The use of magnesium as a therapeutic agent in asthma, myocardial infarction, and pre-eclampsia is also discussed. We suggest addition of magnesium to patients with established cirrhosis in order to reduce the neuromuscular and neuropsychiatric manifestations of chronic liver disease.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with liver cirrhosis

Exclusion criteria

• pregnant women
• Patients with acute or chronic renal failure (cr>1.5)
• Congestive heart failure NYHA 3-4
• Patient with active cancer
• Patients with dementia or mental retardation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

50 participants in 2 patient groups, including a placebo group

magnesium

Experimental group

Description:

will get magnesium for 6 weeks

Treatment:

Dietary Supplement: magnesium

placebo

Placebo Comparator group

Description:

will get placebo for 6 weeks

Treatment:

Dietary Supplement: Placebo